Correspondence | Published:

Proposed endocrine funding priorities for the NICHD strategic plan: expert opinion from the Pediatric Endocrine Society

Pediatric Research (2019) | Download Citation


Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Group, T. S. et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N. Engl. J. Med. 366, 2247–2256 (2012).

  2. 2.

    Consortium, R. Impact of insulin and metformin versus metformin alone on beta-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 41, 1717–1725 (2018).

  3. 3.

    Garvey, K. C. et al. Health care transition in young adults with type 1 diabetes: perspectives of adult endocrinologists in the U.S. Diabetes Care 39, 190–197 (2016).

  4. 4.

    Berman, D. M., Tan, L. L. & Cheng, T. L. Surveys and response rates. Pediatr. Rev. 36, 364–366 (2015).

Download references


We wish to thank the following experts for contributing in-depth descriptions of areas deserving of future research: Sonia Caprio, Madhusmita Misra, Ursula Kaiser, Catherine Gordon, Diva De León-Crutchlow, and Nelly Mauras. We also wish to thank the other members of the Research Affairs Committee of the Pediatric Endocrine Society (Madhusmita Misra, Rose Gubitosi-Klug, Radhika Muzumdar, Yee-Ming Chan, Shanlee Davis, Diva De León-Crutchlow, and Kristina Rother) and the members of the Pediatric Endocrine Society Board of Directors (Phil Zeitler, Erica A. Eugster, Peter A. Lee, Mitchell E. Geffner, Mary Min-chin Lee, Madhusmita Misra, Michael Alan Levine, and Philippe F. Backeljauw) for their careful review of the manuscript and constructive comments. REDCap version of the survey was developed with assistance from Nathalie Lopez and Martin Lai. This work was supported by the UCLA CTSI/NCATS (UL1TR001881 for RedCap), NIH/NIDDK (K08DK101755 to K.S.), and NIH/NHLBI (K23HL125976 to M.L.K.).

Author information


  1. Department of Pediatrics, C.S. Mott Children’s Hospital, University of Michigan Medical School, Ann Arbor, MI, USA

    • Kanakadurga Singer
  2. Joslin Diabetes Center, Massachusetts General Hospital for Children, Boston, MA, USA

    • Michelle L. Katz
  3. Division of Pediatric Endocrinology, UCLA Children’s Discovery and Innovation Institute, David Geffen School of Medicine UCLA, Los Angeles, CA, USA

    • Steven D. Mittelman


  1. Search for Kanakadurga Singer in:

  2. Search for Michelle L. Katz in:

  3. Search for Steven D. Mittelman in:


  1. on behalf of the PES Research Affairs Committee

    Competing interests

    M.L.K. currently works for Eli Lilly & Company. The work presented herein was completed prior to this employment, and Lilly had no input into the study design, the collection, analysis, and interpretation of data, the writing of the report, nor the decision to submit the paper for publication. The other authors declare no competing interests.

    Corresponding author

    Correspondence to Steven D. Mittelman.

    Supplementary information

    About this article

    Publication history